Daniel J. Brennan - 16 Feb 2024 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
20 Feb 2024, 21:03:40 UTC
Prior SEC filing
16 Feb 2024
Next SEC filing
23 May 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Susan Thompson, Attorney-in-Fact

Key filing fact

Daniel J. Brennan filed Form 4 for BOSTON SCIENTIFIC CORP (BSX) on 20 Feb 2024.

Key facts

  • This page summarizes Daniel J. Brennan's Form 4 filing for BOSTON SCIENTIFIC CORP (BSX).
  • 12 reported transactions and 4 derivative rows are listed below.
  • Accepted by SEC: 20 Feb 2024, 21:03.

Change

  • Previous filing in this sequence was filed on 16 Feb 2024.
  • Current net transaction value: -$1,086,974.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BSX transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+4,243
Change %
+1.6%
Price
$0.000000
Shares after
268,812
Date
16 Feb 2024
Ownership
Direct
Footnotes
F1
BSX transaction

Common Stock

Tax liability

Transaction value
$123,873
Shares
-1,882
Change %
-0.7%
Price
$65.82
Shares after
266,930
Date
16 Feb 2024
Ownership
Direct
BSX transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+4,583
Change %
+1.7%
Price
$0.000000
Shares after
271,513
Date
17 Feb 2024
Ownership
Direct
Footnotes
F1
BSX transaction

Common Stock

Tax liability

Transaction value
$133,812
Shares
-2,033
Change %
-0.75%
Price
$65.82
Shares after
269,480
Date
17 Feb 2024
Ownership
Direct
BSX transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+3,706
Change %
+1.4%
Price
$0.000000
Shares after
273,186
Date
18 Feb 2024
Ownership
Direct
Footnotes
F2
BSX transaction

Common Stock

Tax liability

Transaction value
$108,208
Shares
-1,644
Change %
-0.6%
Price
$65.82
Shares after
271,542
Date
18 Feb 2024
Ownership
Direct
BSX transaction

Common Stock

Options Exercise

Transaction value
$178,699
Shares
+13,662
Change %
+5%
Price
$13.08
Shares after
285,204
Date
20 Feb 2024
Ownership
Direct
BSX transaction

Common Stock

Sale

Transaction value
$899,779
Shares
-13,662
Change %
-4.8%
Price
$65.86
Shares after
271,542
Date
20 Feb 2024
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BSX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
$0
Shares
-4,243
Change %
-33%
Price
$0.000000
Shares after
8,486
Date
16 Feb 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
4,243
Exercise price
Footnotes
F1, F3
BSX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
$0
Shares
-4,583
Change %
-50%
Price
$0.000000
Shares after
4,584
Date
17 Feb 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
4,583
Exercise price
Footnotes
F1, F4
BSX transaction Derivative

Deferred Stock Units

Options Exercise

Transaction value
$0
Shares
-3,706
Change %
-100%
Price
$0.000000*
Shares after
0
Date
18 Feb 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3,706
Exercise price
Footnotes
F2, F5
BSX transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
$0
Shares
-13,662
Change %
-100%
Price
$0.000000*
Shares after
0
Date
20 Feb 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
13,662
Exercise price
$13.08
Footnotes
F6
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

Footnote F2

Each deferred stock unit represents the Company's commitment to issue on share of Boston Scientific common stock.

Footnote F3

Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.

Footnote F4

Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant.

Footnote F5

Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant.

Footnote F6

Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .